1-(4-Bromobenzene-1-sulfonyl)piperazine → 2-{1-[4-(4-Bromo-benzenesulfonyl)-piperazin-1-yl]-ethyl}-3-propyl-3H-quinazolin-4-one
Reaction equation
Br[CH:2]([C:4]1[N:13]([CH2:14][CH2:15][CH3:16])[C:12](=[O:17])[C:11]2[C:6](=[CH:7][CH:8]=[CH:9][CH:10]=2)[N:5]=1)[CH3:3].[Br:18][C:19]1[CH:24]=[CH:23][C:22]([S:25]([N:28]2[CH2:33][CH2:32][NH:31][CH2:30][CH2:29]2)(=[O:27])=[O:26])=[CH:21][CH:20]=1>C(O)C>[Br:18][C:19]1[CH:20]=[CH:21][C:22]([S:25]([N:28]2[CH2:33][CH2:32][N:31]([CH:2]([C:4]3[N:13]([CH2:14][CH2:15][CH3:16])[C:12](=[O:17])[C:11]4[C:6](=[CH:7][CH:8]=[CH:9][CH:10]=4)[N:5]=3)[CH3:3])[CH2:30][CH2:29]2)(=[O:27])=[O:26])=[CH:23][CH:24]=1Participants
4
Procedure
A mixture of 2-(1-bromo-ethyl)-3-propyl-3H-quinazolin-4-one (30 mg, 0.1 mmol) and 1-(4-bromo-benzenesulfonyl)-piperazine (47 mg, 0.15 mmol) in ethanol (1 mL) was refluxed overnight. The reaction mixture was then concentrated in vacuo and purified by reverse phase HPLC to yield the product as a white powder (7 mg, 9%). 1H NMR (CDCl3) δ 1.03 (t, 3H, J=5.8 Hz), 1.72 (sex, 2H, J=6.0), 1.80 (d, 3H, J=5.2), 3.48 (m, 6H), 3.90 (m, 3H), 4.23 (m, 1H), 4.77 (q, 1H, J=5.2 Hz), 7.58 (m, 3H), 7.68 (d, 1H, J=6.5 Hz), 7.72 (d, 2H, J=7.1 Hz), 7.81 (t, 1H, J=6.2 Hz), 8.28 (d, 1H, J=6.5 Hz).
Workup
- temperaturewas refluxed overnight
- concentrationThe reaction mixture was then concentrated in vacuo
- custompurified by reverse phase HPLC
Sources & evidence
- ORD record
- ord-74b88ef3f0bb430fb936832d66b3de64
- Source dataset
- uspto-grants-2014_02
- Patent number
- US08642609B2
Reaction notes
Loading…